PMID- 2925242
OWN - NLM
STAT- MEDLINE
DA  - 19890505
DCOM- 19890505
LR  - 20111117
IS  - 0019-9567 (Print)
IS  - 0019-9567 (Linking)
VI  - 57
IP  - 4
DP  - 1989 Apr
TI  - Protective efficacy of protein A-specific antibody against bacteremic infection
      due to Staphylococcus aureus in an infant rat model.
PG  - 1113-8
AB  - Staphylococcal protein A (SpA) is a potent antiphagocytic component of the cell
      wall of most pathogenic Staphylococcus aureus strains. We studied the in vitro
      opsonophagocytic and in vivo protective activities of rabbit immunoglobulin G
      (IgG) antibody to purified SpA obtained from two unencapsulated S. aureus strains
      (Cowan I and 17A). Postimmune serum contained high titers of specific IgG to SpA,
      as measured by a modified enzyme-linked immunosorbent assay that blocked
      nonspecific binding of IgG to SpA. In vitro, both S. aureus strains were
      efficiently phagocytosed and killed by polymorphonuclear leukocytes in the
      presence of nonimmune sera and complement. With one strain (Cowan I),
      opsonophagocytosis was significantly enhanced in the presence of SpA antibody,
      but with the other strain (17A), killing was significantly decreased with immune 
      serum. We then evaluated the potential protective benefit of SpA antibody in
      preventing S. aureus bacteremia in infant rats. Two-day-old rats received saline 
      or various doses of SpA antiserum and were challenged subcutaneously 1 day later,
      but even the highest levels of antibody did not significantly reduce mortality,
      bacteremia or metastatic infection to lungs or liver (frequency or magnitude).
      This lack of protective efficacy was not related to a failure of SpA F(ab')2 to
      bind to cell surface-exposed epitopes, since F(ab')2 fragments prepared from
      hyperimmune serum bound avidly to the whole organism in an enzyme-linked
      immunosorbent assay.
AD  - Department of Pediatrics, University of California at Los Angeles, Torrance
      90509.
FAU - Greenberg, D P
AU  - Greenberg DP
FAU - Bayer, A S
AU  - Bayer AS
FAU - Cheung, A L
AU  - Cheung AL
FAU - Ward, J I
AU  - Ward JI
LA  - eng
GR  - 5T32 HD07245/HD/NICHD NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - UNITED STATES
TA  - Infect Immun
JT  - Infection and immunity
JID - 0246127
RN  - 0 (Antibodies, Bacterial)
RN  - 0 (Immunoglobulin Fab Fragments)
RN  - 0 (Opsonin Proteins)
RN  - 0 (Staphylococcal Protein A)
SB  - IM
MH  - Animals
MH  - Animals, Newborn/*immunology
MH  - Antibodies, Bacterial/analysis/*therapeutic use
MH  - *Antibody Specificity
MH  - Binding Sites, Antibody
MH  - Blood Bactericidal Activity
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Immunization, Passive
MH  - Immunoglobulin Fab Fragments/metabolism
MH  - Opsonin Proteins
MH  - Rats
MH  - Rats, Inbred Strains
MH  - Sepsis/blood/*prevention & control
MH  - Staphylococcal Infections/blood/*prevention & control
MH  - Staphylococcal Protein A/*immunology/metabolism
MH  - Staphylococcus aureus/immunology/metabolism
PMC - PMC313238
OID - NLM: PMC313238
EDAT- 1989/04/01
MHDA- 1989/04/01 00:01
CRDT- 1989/04/01 00:00
PST - ppublish
SO  - Infect Immun. 1989 Apr;57(4):1113-8.